Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT673 and Semaglutide in Type 2 Diabetes and Overweight/Obesity
NCT07724340Phase 2Active, not recruiting
- Sponsor
- Antag Therapeutics
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
A Phase 2 trial of AT673 in type 2 diabetes mellitus (T2DM), obesity, sponsored by Antag Therapeutics. Started Jun 2026; status: active, not recruiting.
02
Drugs
AT673
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07724340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724340.